Regeneron Pharmaceuticals's three largest insider shareholders as of May 30, 2026 are P Roy Vagelos (Chairman Of The Board, 312.58K shares), George Yancopoulos (Bd. Co Chair, President Cso, 310.46K shares), Leonard S Schleifer (Bd. Co Chair, President Ceo, 214.52K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| P Roy Vagelos | Chairman Of The Board | 312,578 | 0 | 24 Mar, 2023 |
| Michael S Brown | - | 0 | 6,162 | 08 Feb, 2023 |
| Christine A Poon | - | 5,219 | 0 | 06 Jan, 2026 |
| N Anthony Coles | - | 1,714 | 0 | 06 Jan, 2026 |
| Leonard S Schleifer | Bd. Co Chair, President Ceo | 214,523 | 0 | 05 Jan, 2026 |
| George L Sing | - | 31,007 | 0 | 06 Jan, 2026 |
| Joseph L Goldstein | - | 6,703 | 0 | 06 Jan, 2026 |
| Neil Stahl | Evp Research And Development | 48,829 | 0 | 18 Dec, 2024 |
| George Yancopoulos | Bd. Co Chair, President Cso | 310,460 | 0 | 05 Jan, 2026 |
| Joseph J Larosa | Evp General Counsel And Secret | 29,517 | 0 | 09 Dec, 2025 |
| Plew Daniel P Van | Evp General Mgr, Industrial | 21,673 | 0 | 11 Dec, 2025 |
| Craig B. Thompson | - | 775 | 0 | 06 Jan, 2026 |
| Marc Tessier-Lavigne | - | 2,434 | 0 | 05 Jan, 2023 |
| David P Schenkein | - | 603 | 0 | 06 Jan, 2026 |
| Robert E Landry | Evp Finance Cfo | 23,693 | 0 | 06 Feb, 2024 |
| Marion Mccourt | Evp Commercial | 14,349 | 0 | 11 Dec, 2025 |
| Huda Y Zoghbi | - | 1,703 | 0 | 23 Feb, 2026 |
| Bonnie L Bassler | - | 1,703 | 0 | 08 Jan, 2026 |
| Christopher R. Fenimore | Evp Finance Cfo | 18,300 | 0 | 09 Dec, 2025 |
| Andrew J Murphy | Evp Research | 47,833 | 0 | 11 Dec, 2025 |
| Kathryn Guarini | - | 603 | 0 | 06 Jan, 2026 |
| Jason Pitofsky | Svp Controller | 4,272 | 0 | 11 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | A | 1,638 | $376.69 | 3,341 | D | M |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | A | 1,638 | $376.69 | 3,341 | D | M |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 49 | $774.68 | 3,292 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 49 | $774.68 | 3,292 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 50 | $775.50 | 3,242 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 50 | $775.50 | 3,242 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 53 | $778.47 | 3,189 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 53 | $778.47 | 3,189 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 208 | $779.55 | 2,981 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 208 | $779.55 | 2,981 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 331 | $780.45 | 2,650 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 331 | $780.45 | 2,650 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 209 | $781.28 | 2,441 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 209 | $781.28 | 2,441 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 298 | $782.10 | 2,143 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 298 | $782.10 | 2,143 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 220 | $783.29 | 1,923 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 220 | $783.29 | 1,923 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 160 | $784.45 | 1,763 | D | S |
| 19 Feb, 2026 | Huda Y Zoghbi | Common Stock | D | 160 | $784.45 | 1,763 | D | S |